M J Robbins

932 total citations
19 papers, 728 citations indexed

About

M J Robbins is a scholar working on Pharmacology, Epidemiology and Clinical Biochemistry. According to data from OpenAlex, M J Robbins has authored 19 papers receiving a total of 728 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pharmacology, 8 papers in Epidemiology and 8 papers in Clinical Biochemistry. Recurrent topics in M J Robbins's work include Bacterial Identification and Susceptibility Testing (8 papers), Antibiotics Pharmacokinetics and Efficacy (7 papers) and Antibiotic Resistance in Bacteria (7 papers). M J Robbins is often cited by papers focused on Bacterial Identification and Susceptibility Testing (8 papers), Antibiotics Pharmacokinetics and Efficacy (7 papers) and Antibiotic Resistance in Bacteria (7 papers). M J Robbins collaborates with scholars based in United Kingdom, India and Jamaica. M J Robbins's co-authors include D. Felmingham, Ian Morrissey, D. J. Farrell, William G. Love, David J. Farrell, W. Rhys‐Williams, R. N. Grüneberg, G.L. Ridgway, G L Ridgway and Rosemary J. Burnett and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, Journal of Antimicrobial Chemotherapy and Drugs.

In The Last Decade

M J Robbins

18 papers receiving 658 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M J Robbins United Kingdom 12 403 190 179 126 110 19 728
Giovanni Bonfiglio Italy 18 196 0.5× 433 2.3× 252 1.4× 25 0.2× 78 0.7× 41 807
L. Gualco Italy 12 470 1.2× 360 1.9× 103 0.6× 115 0.9× 128 1.2× 24 794
Mark E. Jones United States 13 402 1.0× 743 3.9× 210 1.2× 53 0.4× 170 1.5× 14 1.2k
Barbara G. Painter United States 14 253 0.6× 197 1.0× 292 1.6× 52 0.4× 229 2.1× 24 800
Mark W. Garrison United States 15 289 0.7× 232 1.2× 298 1.7× 23 0.2× 356 3.2× 33 909
Zoi Dorothea Pana Cyprus 10 367 0.9× 375 2.0× 112 0.6× 28 0.2× 362 3.3× 29 886
J. P. Maskell United Kingdom 17 263 0.7× 174 0.9× 150 0.8× 16 0.1× 195 1.8× 35 705
Fevronia Kolonitsiou Greece 17 225 0.6× 188 1.0× 77 0.4× 24 0.2× 392 3.6× 75 851
Ronald N. Master United States 9 367 0.9× 246 1.3× 72 0.4× 80 0.6× 82 0.7× 16 597
K. Dornbusch Sweden 16 305 0.8× 593 3.1× 306 1.7× 21 0.2× 214 1.9× 47 1.1k

Countries citing papers authored by M J Robbins

Since Specialization
Citations

This map shows the geographic impact of M J Robbins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M J Robbins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M J Robbins more than expected).

Fields of papers citing papers by M J Robbins

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M J Robbins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M J Robbins. The network helps show where M J Robbins may publish in the future.

Co-authorship network of co-authors of M J Robbins

This figure shows the co-authorship network connecting the top 25 collaborators of M J Robbins. A scholar is included among the top collaborators of M J Robbins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M J Robbins. M J Robbins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Farrell, David J., M J Robbins, W. Rhys‐Williams, & William G. Love. (2010). In vitro activity of XF-73, a novel antibacterial agent, against antibiotic-sensitive and -resistant Gram-positive and Gram-negative bacterial species. International Journal of Antimicrobial Agents. 35(6). 531–536. 42 indexed citations
2.
Farrell, David J., M J Robbins, W. Rhys‐Williams, & William G. Love. (2010). Investigation of the Potential for Mutational Resistance to XF-73, Retapamulin, Mupirocin, Fusidic Acid, Daptomycin, and Vancomycin in Methicillin-Resistant Staphylococcus aureus Isolates during a 55-Passage Study. Antimicrobial Agents and Chemotherapy. 55(3). 1177–1181. 79 indexed citations
3.
Morrissey, Ian, et al.. (2005). Antimicrobial susceptibility of community-acquired respiratory tract pathogens in the UK during 2002/3 determined locally and centrally by BSAC methods. Journal of Antimicrobial Chemotherapy. 55(2). 200–208. 17 indexed citations
4.
5.
Farrell, D. J., et al.. (2003). A UK Multicentre Study of the Antimicrobial Susceptibility of Bacterial Pathogens Causing Urinary Tract Infection. Journal of Infection. 46(2). 94–100. 250 indexed citations
6.
Felmingham, D., et al.. (1998). Antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens isolated in the UK during the 1995-1996 cold season. Journal of Antimicrobial Chemotherapy. 41(3). 411–415. 29 indexed citations
7.
Ridgway, G.L., et al.. (1997). The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp. Journal of Antimicrobial Chemotherapy. 40(suppl 1). 31–34. 36 indexed citations
8.
Felmingham, D., et al.. (1997). In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates. Journal of Antimicrobial Chemotherapy. 39(suppl 2). 43–49. 62 indexed citations
9.
Felmingham, D., M J Robbins, Gopal Chandra Ghosh, et al.. (1994). An in vitro characterization of cefditoren, a new oral cephalosporin.. PubMed. 20(4). 127–47. 27 indexed citations
10.
Felmingham, D., M J Robbins, Gargi Ghosh, et al.. (1993). Comparative In Vitro Activity of PD 131628, the Microbiologically Active Constituent of the Prodrug CI-990 (PD 131112). Drugs. 45(Supplement 3). 188–189. 2 indexed citations
11.
Felmingham, D. & M J Robbins. (1992). In vitro activity of lomefloxacin and other antimicrobials against bacterial enteritis pathogens. Diagnostic Microbiology and Infectious Disease. 15(4). 339–343. 3 indexed citations
12.
Felmingham, D., et al.. (1991). The in vitro activity of some 14-, 15- and 16- membered macrolides against Staphylococcus spp., Legionella spp., Mycoplasma spp. and Ureaplasma urealyticum.. PubMed. 17(2). 91–9. 38 indexed citations
13.
Robbins, M J, et al.. (1989). Comparative in vitro activity of lomefloxacin, a difluoro-quinolone. Diagnostic Microbiology and Infectious Disease. 12(3). 65–76. 14 indexed citations
14.
Grüneberg, R. N., et al.. (1988). The comparative in-vitro activity of ofloxacin. Journal of Antimicrobial Chemotherapy. 22(Supplement_C). 9–19. 43 indexed citations
15.
Tillotson, Glenn, et al.. (1988). Identification ofCorynebacterium jeikeium andCorynebacterium CDC group D 2 with the API 20 strep system. European Journal of Clinical Microbiology & Infectious Diseases. 7(5). 675–678. 8 indexed citations
16.
Robbins, M J, Richard Marais, D. Felmingham, & G L Ridgway. (1987). The in-vitro activity of doxycycline and minocycline against anaerobic bacteria. Journal of Antimicrobial Chemotherapy. 20(3). 379–382. 8 indexed citations
17.
Robbins, M J, et al.. (1987). In vitro activity of aztreonam, cefuroxime and ceftazidime against gram-negative rods isolated from hospital patients with urinary tract infection.. PubMed. 7(3). 203–5. 1 indexed citations
18.
Felmingham, D., M J Robbins, Richard Marais, G L Ridgway, & R. N. Grüneberg. (1987). The effect of carbon dioxide on the in vitro activity of erythromycin and RU-28965 against anaerobic bacteria.. PubMed. 13(4). 195–9. 2 indexed citations
19.
Robbins, M J, Richard Marais, D. Felmingham, G.L. Ridgway, & R. N. Grüneberg. (1987). In vitro activity of vancomycin and teicoplanin against anaerobic bacteria.. PubMed. 13(9). 551–4. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Giovanni Bonfiglio Breakdown of academic impact, for papers by L. Gualco Breakdown of academic impact, for papers by Mark E. Jones Breakdown of academic impact, for papers by Barbara G. Painter Breakdown of academic impact, for papers by Mark W. Garrison Breakdown of academic impact, for papers by Zoi Dorothea Pana Breakdown of academic impact, for papers by J. P. Maskell Breakdown of academic impact, for papers by Fevronia Kolonitsiou Breakdown of academic impact, for papers by Ronald N. Master Breakdown of academic impact, for papers by K. Dornbusch
Rankless by CCL
2026